Bayer Ag · XETR:BAYN

Bayer — 25th European Society of Retina Specialists (EURETINA) 2025

11 slides from Bayer's conference presentation, September 2025

  1. Slide 1: Results from the QUASAR Study: Comparable Vision Gains with Aflibercept 8 mg and 2 mg in RVO

    Results from the QUASAR Study: Comparable Vision Gains with Aflibercept 8 mg and 2 mg in Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion Varun Chaudhary,1 Richard Gale,2,3 Seenu M. Hariprasad,4 Motohiro Kamei,5 Youxin Chen,6 Ramin Khoramnia,7,8 Andrew Chang,9 Lynne Brunck,10 Rose G

  2. Slide 2: Disclosures

    Disclosures • Varun Chaudhary receives grants from Bayer, Novartis, and Roche; and serves on advisory boards for Alcon, Apellis, Bayer, Boehringer Ingelheim, Novartis, and Roche • RG is a consultant for AbbVie, Allergan, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ocular Therap

  3. Slide 3: QUASAR: Study Design

    QUASAR: Study Design A multi-center, randomized, double-masked, Phase 3 study in patients with treatment-naïve macular edema secondary to RVO Randomized at baseline 1 (2q4) : 1 (8q8/3) : 1 (8q8/5) 2q4 8q8/3 8q8/5 Aflibercept 8 mg every 8 weeks, Aflibercept 8 mg every 8 weeks, Aflibercept 2 mg every

  4. Slide 4: Both Groups Achieved Non-inferior BCVA Gains Compared to Aflibercept 2 mg at Week 36

    Both Aflibercept 8 mg Groups Achieved Non-inferior BCVA Gains Compared to Aflibercept 2 mg at Week 36, with Fewer Injections Overall and Across RVO Subtypes 20 BRVO LS mean change from BL in BCVA, ETDRS letters 15 Overall RVO Population 10 LS mean 1-sided test for Mean change from non-inferiority at

  5. Slide 5: Both Groups Achieved Robust CRT Reductions Compared to Aflibercept 2 mg at Week 36

    Both Aflibercept 8 mg Groups Achieved Robust CRT Reductions Compared to Aflibercept 2 mg at Week 36, with Fewer Injections Overall and Across RVO Subtypes BRVO Time (weeks) 0 4 8 12 16 20 24 28 32 36 0 Overall RVO Population LS mean change from BL LS mean change LS mean number of injections from BL

  6. Slide 6: Last Assigned Dosing Interval at Week 36 for Patients Eligible for Interval Extension

    Last Assigned Dosing Interval at Week 36 for Patients Eligible for Interval Extension: Overall Population, BRVO, and CRVO/HRVO Subtypes Overall RVO Population BRVO CRVO/HRVO Q4 Q4 Q4 24.4% 20.6% 28.1% 2q4 2q4 2q4 (n=287) Q8 (n=141) Q8 (n=146) Q8 75.6% 79.4% 71.9% ≥Q8 ≥Q8 ≥Q8 Q4 93.9 Q4 94.0 Q4 93.8

  7. Slide 7: BRVO Case Study: Baseline Visit

    BRVO Case Study: Baseline Visit Baseline patient characteristics Age, years 52 Gender Female Ethnicity White Type of RVO BRVO, right eye Treatment arm 8q8/3 Baseline BCVA, 35 ETDRS letters Late frame angiogram Baseline CRT, μm 925 at baseline visit shows Past medical history None extensive leakage o

  8. Slide 8: BRVO Case Study: Week weeks after injection #1

    BRVO Case Study: Week 4 4 weeks after aflibercept 8 mg injection #1 Baseline BCVA, ETDRS letters Baseline CRT, pm . Baseline BCVA, ETDRS letters (Change from baseline) CRT, pm (Change from baseline) Current treatment interval nt received | monthly dose)

  9. Slide 9: BRVO Case Study: Week 12 (reference visit)

    BRVO Case Study: Week 12 (reference visit) 4 weeks after aflibercept 8 mg injection #3 (third initial monthly dose) Baseline BCVA, ETDRS letters Baseline CRT, pm BCVA, ETDRS letters (Change from baseline) CRT, pm (Change from baseline) Current treatment interval jection was Baseline on willl : No de

  10. Slide 10: BRVO Case Study: Week 36

    BRVO Case Study: Week 36 4 weeks after aflibercept 8 mg injection #6 Baseline Baseline BCVA, ETDRS letters 35 Baseline CRT, μm 925 Week 36 Week 36 BCVA, ETDRS letters 85 (Change from baseline) (+50) CRT, μm 250 (Change from baseline) (−675) Current treatment interval Q8 No detectable leakage of fluo

  11. Slide 11: QUASAR: Paradigm Shift in the Treatment of RVO with Aflibercept 8 mg

    QUASAR: Paradigm Shift in the Treatment of RVO with Aflibercept 8 mg • Aflibercept 8q8/3 and 8q8/5 groups achieved non-inferior BCVA gains and robust reductions in CRT, with fewer injections than in the aflibercept 2q4 group at Week 36, overall and across BRVO and CRVO/HRVO subtypes • Approximately

Bayer — 25th European Society of Retina Specialists (EURETINA) 2025 on 6ix